Skip to Content
Find More Like This
Return to Search

TARGETS IN BREAST CANCER FOR PROGNOSIS OR THERAPY

United States Patent Application

20090203051
A1
View the Complete Application at the US Patent & Trademark Office
Lawrence Berkeley National Laboratory - Visit the Technology Transfer and Intellectual Property Management Department Website
Cancer markers are developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genome wide analyses of genome copy number and gene expression in breast cancer revealed 66 genes in the human chromosomal regions, 8p11, 11q13, 17q12, and 20q13 that were amplified. Diagnosis and assessment of amplification levels of genes shown to be amplified are useful in prediction of patient outcome of a of patient's response and drug resistance in breast cancer. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically breast cancer. Inhibitors of these genes will be useful therapies for treatment of these non-responsive cancers.
Gray, Joe W. (San Francisco, CA), Fridlyand, Jane (Berkeley, CA), Neve, Richard (San Mateo, CA), Spellman, Paul (Benicia, CA), Chin, Koei (Foster City, CA), Hu, Zhi (El Cerrito, CA), Waldman, Frederic (San Francisco, CA)
The Regents of the University of California (Oakland CA)
12/ 330,386
December 8, 2008
STATEMENT OF GOVERNMENTAL SUPPORT [0002] This invention was made during work supported by the National Cancer Institute, through Grants CA 58207 and CA 112970, and during work supported by the U.S. Department of Energy under Contract No. DE-AC03-76SF00098, now DE-AC02-05CH11231. The government has certain rights in this invention.